FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatin

References

• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97–5.
   PubMed Web of Science ®Google Scholar
• Serrano-Del Valle A, Anel A, Naval J, Marzo I. Immunogenic cell death and Immunotherapy of Multiple Myeloma. Front Cell Dev Biol. 2019;7:50. doi:10.3389/fcell.2019.00050.
   PubMed Web of Science ®Google Scholar
• Garg AD, Agostinis P. Cell death and immunity in cancer: from danger signals to mimicry of pathogen defense responses. Immunol Rev. 2017;280:126–148. doi:10.1111/imr.12574.
   PubMed Web of Science ®Google Scholar
• Vanmeerbeek I, Sprooten J, De Ruysscher D, Tejpar S, Vandenberghe P, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. et al. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. Oncoimmunology. 2020;9(1):1703449. doi:10.1080/2162402X.2019.1703449.
   PubMed Web of Science ®Google Scholar
• Kepp O, Sauvat A, Leduc M, Forveille S, Liu P, Zhao L, Bezu L, Xie W, Zitvogel L, Kroemer G. et al. A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers. Oncoimmunology. 2019;8(8):1606665. doi:10.1080/2162402X.2019.1606665.
   PubMed Web of Science ®Google Scholar
• Humeau J, Levesque S, Kroemer G, Pol JG. Gold Standard Assessment of Immunogenic Cell death in Oncological Mouse Models. Methods Mol Biol. 2019;1884:297–315.
   PubMedGoogle Scholar
• Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N. et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3(9):e955691. doi:10.4161/21624011.2014.955691.
   PubMed Web of Science ®Google Scholar
• Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N. et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene. 2011;30(10):1147–1158. doi:10.1038/onc.2010.500.
   PubMed Web of Science ®Google Scholar
• Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I, Salek C, Strnad P, Kroemer G, Galluzzi L. et al. Prognostic and predictive value of DAMPs and DAMP-Associated processes in Cancer. Front Immunol. 2015;6:402. doi:10.3389/fimmu.2015.00402.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M. et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science. 2015;350:972–978. doi:10.1126/science.aad0779.
   PubMed Web of Science ®Google Scholar
• Aurelius J, Mollgard L, Kiffin R, Ewald Sander F, Nilsson S, Thoren FB, Hellstrand K, Martner A. Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML. Leuk Lymphoma. 2019;60(11):2771–2778. doi:10.1080/10428194.2019.1599110.
   PubMed Web of Science ®Google Scholar
• Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S. et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25(6):920–928. doi:10.1038/s41591-019-0432-4.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R. et al. Overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342–2350. doi:10.1056/NEJMoa1809697.
   PubMed Web of Science ®Google Scholar
• Pol JG, Caudana P, Paillet J, Piaggio E, Kroemer G. Effects of interleukin-2 in immunostimulation and immunosuppression. J Exp Med. 2020;217.
   Web of Science ®Google Scholar
• Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR. et al. Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. Br J Cancer. 2018;118(10):1322–1328. doi:10.1038/s41416-018-0085-y.
   PubMed Web of Science ®Google Scholar
• Abrahamsson H, Jensen BV, Berven LL, Nielsen DL, Saltyte Benth J, Johansen JS, Larsen FO, Johansen JS, Ree AH. Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation: 8-12 years of follow-up. Int J Cancer. 2020;146:2019–2026. doi:10.1002/ijc.32847.
   PubMed Web of Science ®Google Scholar
• Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD. et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018;24:1178–1191. doi:10.1038/s41591-018-0085-8.
   PubMed Web of Science ®Google Scholar
• Lisovsky M, Braun SE, Ge Y, Takahira H, Lu L, Savchenko VG, Lyman SD, Broxmeyer HE. Flt3-ligand production by human bone marrow stromal cells. Leukemia. 1996;10:1012–1018.
   PubMed Web of Science ®Google Scholar
• Durai V, Bagadia P, Briseno CG, Theisen DJ, Iwata A, JTt D. et al. Altered compensatory cytokine signaling underlies the discrepancy between Flt3(-/-) and Flt3l(-/-) mice. J Exp Med. 2018;215:1417–1435. doi:10.1084/jem.20171784.
   PubMed Web of Science ®Google Scholar
• Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med. 2003;198(2):305–313. doi:10.1084/jem.20030323.
   PubMed Web of Science ®Google Scholar
• Greystoke A, O’Connor JP, Linton K, Taylor MB, Cummings J, Ward T, Maders F, Hughes A, Ranson M, Illidge TM. et al. Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. Br J Cancer. 2011;104(4):719–725. doi:10.1038/sj.bjc.6606082.
   PubMed Web of Science ®Google Scholar
• Wodnar-Filipowicz A, Lyman SD, Gratwohl A, Tichelli A, Speck B, Nissen C. Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood. 1996;88(12):4493–4499. doi:10.1182/blood.V88.12.4493.bloodjournal88124493.
   PubMed Web of Science ®Google Scholar
• Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, Casanova-Acebes M, Khudoynazarova M, Agudo J, Tung N. et al. Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor site enhances Tumor responses to Therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44(4):924–938. doi:10.1016/j.immuni.2016.03.012.
   PubMed Web of Science ®Google Scholar
• Hammerich L, Marron TU, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S, Zhan Y, Ostrowski D, Yellin M, Marsh H. et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25(5):814–824. doi:10.1038/s41591-019-0410-x.
   PubMed Web of Science ®Google Scholar
• Liu D, Jenkins RW, Sullivan RJ. Mechanisms of resistance to Immune Checkpoint Blockade. Am J Clin Dermatol. 2019;20:41–54. doi:10.1007/s40257-018-0389-y.
   PubMed Web of Science ®Google Scholar
• Levesque S, Le Naour J, Pietrocola F, Paillet J, Kremer M, Castoldi F, Baracco EE, Wang Y, Vacchelli E, Stoll G. et al. A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. Oncoimmunology. 2019;8(11):e1657375. doi:10.1080/2162402X.2019.1657375.
   PubMed Web of Science ®Google Scholar
• Gujar S, Pol JG, Kroemer G. Heating it up: oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies. Oncoimmunology. 2018;7:e1442169. doi:10.1080/2162402X.2018.1442169.
   PubMed Web of Science ®Google Scholar
• Liu P, Zhao L, Kepp O, Kroemer G. Crizotinib – a tyrosine kinase inhibitor that stimulates immunogenic cell death. Oncoimmunology. 2019;20(7):1596652. doi:10.1080/2162402X.2019.1596652.
   Web of Science ®Google Scholar
• Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K. et al. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nat Commun. 2019;10(1):1486. doi:10.1038/s41467-019-09415-3.
   PubMed Web of Science ®Google Scholar
• Manukian G, Bar-Ad V, Lu B, Argiris A, Johnson JM. Combining Radiation and Immune Checkpoint Blockade in the treatment of Head and Neck Squamous Cell Carcinoma. Front Oncol. 2019;9:122. doi:10.3389/fonc.2019.00122.
   PubMed Web of Science ®Google Scholar
• Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, Yamazaki T, Poirier-Colame V, Newton A, Redouane Y. et al. Immunogenic Chemotherapy sensitizes Tumors to Checkpoint Blockade Therapy. Immunity. 2016;44(2):343–354. doi:10.1016/j.immuni.2015.11.024.
   PubMed Web of Science ®Google Scholar
• Sivanandam V, LaRocca CJ, Chen NG, Fong Y, Warner SG, Viruses O. Immune Checkpoint Inhibition: the best of both Worlds. Mol Ther Oncolytics. 2019;13:93–106. doi:10.1016/j.omto.2019.04.003.
   PubMed Web of Science ®Google Scholar
• Xie W, Mondragon L, Mauseth B, Wang Y, Pol J, Levesque S, Zhou H, Yamazaki T, Eksteen JJ, Zitvogel L. et al. Tumor lysis with LTX-401 creates anticancer immunity. Oncoimmunology. 2019;8(7):1594555. doi:10.1080/2162402X.2019.1594555.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Pitt JM, Vetizou M, Marabelle A, Flores C, Rekdal Ø, Kroemer G, Zitvogel L. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade. Cell Death Differ. 2016;23(6):1004–1015. doi:10.1038/cdd.2016.35.
   PubMed Web of Science ®Google Scholar
• Cauwels A, Van Lint S, Paul F, Garcin G, De Koker S, Van Parys A, Wueest T, Gerlo S, Van der Heyden J, Bordat Y. et al. Delivering Type I Interferon to Dendritic Cells empowers Tumor Eradication and Immune combination treatments. Cancer Res. 2018;78(2):463–474. doi:10.1158/0008-5472.CAN-17-1980.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Shin H, Han J, Na K. Combination of photodynamic therapy (PDT) and anti-tumor immunity in cancer therapy. J Pharm Investig. 2018;48(2):143–151. doi:10.1007/s40005-017-0377-x.
   PubMedGoogle Scholar
• Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani J, Hannani D, Duret H, Steegh K. et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38(4):729–741. doi:10.1016/j.immuni.2013.03.003.
   PubMed Web of Science ®Google Scholar
• Yang H, Xia L, Chen J, Zhang S, Martin V, Li Q. et al. Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity. Nat Med. 2019;25:1428–1441. doi:10.1038/s41591-019-0566-4.
   PubMed Web of Science ®Google Scholar